Nurix Therapeutics, Inc. NRIX Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities
Deferred issuance costs included in accounts payable and accrued expenses and other current liabilities at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept nrix:DeferredIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilities.
The official record: Nurix Therapeutics, Inc.’s 10-K, filed January 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s deferred issuance costs included in accounts payable and accrued expenses and other current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s deferred issuance costs included in accounts payable and accrued expenses and other current liabilities?
- Nurix Therapeutics, Inc. (NRIX) reported deferred issuance costs included in accounts payable and accrued expenses and other current liabilities of $0 in Q3 2025.
- How has Nurix Therapeutics, Inc.'s deferred issuance costs included in accounts payable and accrued expenses and other current liabilities changed year-over-year?
- Nurix Therapeutics, Inc.'s deferred issuance costs included in accounts payable and accrued expenses and other current liabilities decreased by 100.0% year-over-year, from $29.25K to $0.
- What does deferred issuance costs included in accounts payable and accrued expenses and other current liabilities mean?
- This represents costs incurred in connection with a planned or completed equity financing that are deferred and recorded within accounts payable or accrued expenses. These costs are typically amortized or offset against the proceeds of the financing. It provides transparency into the timing and nature of expenses associated with capital market transactions.